Company news

Cogent Biosciences, Inc. news in 2026

Cogent Biosciences, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Cogent Biosciences to Participate in the Guggenheim Healthcare Innovation Conference

October 27, 2026

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM)

September 15, 2026

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

August 10, 2026

Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM)

June 30, 2026

Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress

June 12, 2026

Cogent Biosciences Announces Detailed Data from APEX Pivotal Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis at the 2026 European Hematology Association (EHA) Congress

June 12, 2026

Cogent Biosciences Announces Detailed Clinical Data from PEAK Phase 3 Trial with Bezuclastinib in Combination with Sunitinib in Gastrointestinal Stromal Tumors (GIST) at 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

May 29, 2026

Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) with Priority Review for Bezuclastinib in Combination with Sunitinib for Patients with GIST

May 28, 2026

Cogent Biosciences Announces Participation in the 2026 Jefferies Global Healthcare Conference

May 26, 2026

Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress

May 12, 2026

Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results

May 5, 2026

Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

April 20, 2026

Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026

April 17, 2026

Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)

March 15, 2026

Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting

February 27, 2026

Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results

February 17, 2026

Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting

February 10, 2026

Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)

January 25, 2026

Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)

January 20, 2026

Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio

January 11, 2026

Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference

January 5, 2026

Decks in 2026